Key Takeaways

  • Extra ablation did not help patients overall.
  • It helped those with low-voltage heart tissue.
  • The trial ran at 14 Canadian centres.

A Canadian Trial With a Split Answer

What if doing more to the heart during surgery doesn't actually help most patients?

A Canadian clinical trial has found exactly that — but with an important exception.

The COAST-AF trial, led by the University of Ottawa Heart Institute, found that adding extra ablation during treatment for persistent atrial fibrillation (AF) did not significantly improve results across all patients. However, patients with a particular type of abnormal heart tissue saw a clear benefit.

The study, published in JAMA, randomized 508 patients across 14 Canadian ablation centres.

Half received standard pulmonary vein isolation (PVI). The other half received PVI plus ablation targeting abnormal low-voltage areas of heart tissue.

Patients were followed for 18–36 months under principal investigator Dr. Pablo Nery.

The numbers

Across all 508 patients, adding more ablation failed to significantly reduce the return of atrial arrhythmias.

Recurrence occurred in 49.4% of patients who received the extra ablation, compared with 57.5% who received PVI alone.

The difference was not statistically significant (hazard ratio 0.82, p = .11).

But then researchers looked at a specific group of patients — and the results changed.

Among the 268 patients who actually had low-voltage areas in their heart tissue, the additional procedure made a significant difference.

Recurrence dropped to 49.3% with extra ablation, compared with 69.2% with standard PVI alone (hazard ratio 0.77, p = .002).

That's a substantial difference.

For patients without low-voltage areas, however, the additional ablation offered no benefit.

Safety outcomes were similar between the groups, although procedures involving extra ablation took longer.

The honesty beat

The findings come with an important distinction.

The trial's main question was whether additional ablation helps everyone with persistent AF. The answer was no.

The encouraging results came from a subgroup of patients who had the specific tissue abnormalities targeted by the procedure.

The authors caution that this finding should be viewed as a strong signal for tailoring treatment, not proof.

As Dr. Nery put it, the results highlight "the importance of tailoring treatment to the individual rather than taking a one-size-fits-all approach."

The study involved patients with persistent AF treated at Canadian ablation centres. Its findings do not speak to other AF types or treatments.

Health note: This article summarizes a published clinical trial for information only and is not medical advice. AF treatment decisions belong with your cardiology team.

The Twikup Take

"More treatment" doesn't automatically mean "better treatment." This Canadian trial shows why identifying the right patients matters: the extra procedure made a difference in those with the tissue abnormalities it was designed to target, but not everyone else.

The future of better treatment may be knowing when NOT to do more.

Image: Illustrative image.

Sources